MIACALCIN Nasal Spray is provided in 3.7-mL fill glass bottles as a solution for nasal administration. There is sufficient medication for 30 doses. Each milliliter contains calcitonin-salmon 2200 IU (corresponding to 200 IU per 0.09 ML actuation), sodium chloride 8.5 mg, benzalkonium chloride 0.10 mg, nitrogen, hydrochloric acid (added as necessary to adjust pH), and purified water.

MIACALCIN Nasal Spray is indicated for the treatment of osteoporosis in women more than 5 years after menopause with low bone mass. MIACALCIN Nasal Spray should be reserved for patients who refuse or cannot tolerate estrogens or in whom estrogens are contraindicated. Use of MIACALCIN Nasal Spray is recommended in conjunction with adequate calcium and vitamin D intake to retard the progressive loss of bone mass.

MIACALCIN Nasal Spray is an appropriate choice for many patients

	With GI problems
	Taking multiple medications
	In long-term care facilities
	With limited mobility
	Who are unable to follow complicated daily or weekly dosing instructions

Rhinitis, other nasal symptoms, back pain, arthralgia, epistaxis, and headache were the most common adverse events. Because calcitonin-salmon is a protein, the potential for a systemic allergic reaction exists. In rare cases, nasal ulcerations were reported that required temporary discontinuation of therapy until healing occurred.

For further information, please consult the complete Prescribing Information.

Home | Professional Main Page | Treatment Guidelines
MIACALCIN Nasal Spray | Patient Challenges | Patient Education
Resources | Prescribing Information